MX2024008840A - Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. - Google Patents
Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.Info
- Publication number
- MX2024008840A MX2024008840A MX2024008840A MX2024008840A MX2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A
- Authority
- MX
- Mexico
- Prior art keywords
- oxazepine
- pyrido
- pyrrolo
- tetrahydro
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- YIOBXTCJTWWMJA-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazepine Chemical compound O1C=CC=NC2=CC=CN=C12 YIOBXTCJTWWMJA-UHFFFAOYSA-N 0.000 title 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008840A true MX2024008840A (es) | 2024-07-25 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008840A MX2024008840A (es) | 2022-01-21 | 2023-01-20 | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (https=) |
| EP (1) | EP4466273A1 (https=) |
| JP (2) | JP7714811B2 (https=) |
| KR (1) | KR20240136972A (https=) |
| CN (1) | CN119053610A (https=) |
| AR (1) | AR128310A1 (https=) |
| AU (1) | AU2023210279A1 (https=) |
| CA (1) | CA3242074A1 (https=) |
| CO (1) | CO2024009334A2 (https=) |
| IL (1) | IL312709A (https=) |
| MX (1) | MX2024008840A (https=) |
| TW (1) | TW202340210A (https=) |
| WO (1) | WO2023141536A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | １，３，４，７－四氫－２Ｈ－吡咯并［３＇，２＇：５，６］吡啶并［２，３－ｂ］［１，４］氮呯Ｂｃｌ－２抑制劑 |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511748B (zh) | 2017-08-23 | 2023-05-02 | 广州麓鹏制药有限公司 | Bcl-2抑制剂 |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| JP7849296B2 (ja) | 2020-02-24 | 2026-04-21 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体 |
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | １，３，４，７－四氫－２Ｈ－吡咯并［３＇，２＇：５，６］吡啶并［２，３－ｂ］［１，４］氮呯Ｂｃｌ－２抑制劑 |
-
2023
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023141536A1 (en) | 2023-07-27 |
| IL312709A (en) | 2024-07-01 |
| US20250066388A1 (en) | 2025-02-27 |
| US11964990B2 (en) | 2024-04-23 |
| AR128310A1 (es) | 2024-04-17 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| JP2025160251A (ja) | 2025-10-22 |
| JP2025504382A (ja) | 2025-02-12 |
| CN119053610A (zh) | 2024-11-29 |
| AU2023210279A1 (en) | 2024-05-23 |
| US20260028356A1 (en) | 2026-01-29 |
| CO2024009334A2 (es) | 2024-07-18 |
| KR20240136972A (ko) | 2024-09-19 |
| CA3242074A1 (en) | 2023-07-27 |
| EP4466273A1 (en) | 2024-11-27 |
| JP7714811B2 (ja) | 2025-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500017A1 (en) | Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2025010928A (es) | Compuestos de alquinil quinazolina | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2024008840A (es) | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. | |
| MX2026003002A (es) | Inhibidores de kras | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MXPA05001581A (es) | Algunas imidazopiridinas novedosas y su uso. | |
| DK1159279T3 (da) | 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler | |
| MX2024013065A (es) | Inhibidores de amida heterociclica biciclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2024013095A (es) | Compuestos inhibidores de fgfr2 | |
| MX2024008868A (es) | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. | |
| MA27566A1 (fr) | Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 | |
| MX2025000174A (es) | Compuestos y metodos terapeuticos. | |
| MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MXPA05009688A (es) | Derivados de naftiridina como agentes antibacterianos. | |
| SE0302756D0 (sv) | Novel Compounds | |
| WO2003008412A3 (en) | Hetero-bicyclic crf antagonists | |
| SI1511472T1 (sl) | Spojine uporabne pri zdravljenju antraksa in inhibiranju letalnega faktorja | |
| MX2025013372A (es) | Inhibidores de gsk3\03b1 y metodos de uso de estos | |
| MX2023014827A (es) | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. | |
| MX2024005063A (es) | Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos. |